Last reviewed · How we verify
Folfox plus Bevacizumab and reolysin
Folfox plus Bevacizumab and reolysin is a combination chemotherapy regimen that targets rapidly dividing cancer cells and inhibits angiogenesis.
Folfox plus Bevacizumab and reolysin is a combination chemotherapy regimen that targets rapidly dividing cancer cells and inhibits angiogenesis. Used for Metastatic colorectal cancer.
At a glance
| Generic name | Folfox plus Bevacizumab and reolysin |
|---|---|
| Sponsor | Canadian Cancer Trials Group |
| Drug class | chemotherapy regimen |
| Target | VEGF, thymidylate synthase, DNA repair |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Folfox is a combination of fluorouracil, leucovorin, and oxaliplatin, which work together to inhibit thymidylate synthase and DNA repair, ultimately leading to cell death. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), preventing angiogenesis and tumor growth. Reolysin is a reovirus that selectively infects and kills cancer cells by inducing apoptosis.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Fatigue
- Nausea and vomiting
- Diarrhea
- Neutropenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: